 |
|
|
| |
A Fixed-Dose Combination of Sofosbuvir and Ledipasvir
Is Highly Effective in Treatment-Naïve and
Treatment-Experienced Genotype 1 HCV-Infected Patients:
Results from the LONESTAR and ELECTRON Phase 2 Studies
|
| |
| |
Reported by Jules Levin
HEP DART 2013, December 8-12, 2013, Big Island, HI, USA
AASLD: Gilead at AASLD: Sofosbuvir for GT 3, 2 and 1 - (11/18/13)
AASLD: Gilead at AASLD: 2 - (11/18/13)
AASLD: Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/02/13)
AASLD: BMS at AASLD - (11/18/13)
64rd Annual Meeting of the American Association for the Study of Liver Diseases
Washington, DC Nov 1-5 2013
Reported by Jules Levin
HEP DART 2013; Big Island, HI, USA
Eric Lawitz1,2, Catherine Stedman3, Fred F. Poordad1,2,
Phillip S. Pang4, Xiao Ding4, Robert H. Hyland4, William T. Symonds4,
Fernando E. Membreno1,2, Edward Gane5
1Texas Liver Institute, San Antonio, TX; 2University of Texas Health Science Center, San Antonio, TX; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand; 4Gilead Sciences, Inc, Foster City, CA;
5Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
